A retrospective study analysing outcomes associated with monoclonal antibody use in pregnant persons with mild-to-moderate coronavirus disease 2019
Latest Information Update: 09 Feb 2022
At a glance
- Drugs Bamlanivimab (Primary) ; Casirivimab/imdevimab (Primary) ; Etesevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 09 Feb 2022 New trial record
- 03 Feb 2022 Results published in the Obstetrics and Gynecology